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Abstract Sox10 regulates melanocyte development at least
partly through its stimulatory e¡ect on Mitf gene expression.
Here, we characterize the gene for dopachrome tautomerase
(Dct/Trp2) as the second direct Sox10 target in melanocytes,
arguing for the existence of Sox10 functions in melanocytes that
are independent of its epistatic relationship to Mitf. Sox10 re-
sponsiveness was mediated by multiple binding sites within the
proximal Dct/Trp2 promoter which display varying a⁄nities
and bind Sox10 monomers or dimers. Mitf synergistically en-
hanced Sox10-dependent activation of the Dct/Trp2 promoter.
Synergy appears mechanistically complex and requires both di-
rect binding of Sox10 to the promoter and the protein’s trans-
activation domain.
+ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Sox10 is a member of the Sox family of transcription fac-
tors [1,2]. Unlike other proteins that contain a high-mobility-
group box as their DNA binding domain, many Sox proteins,
including Sox10, are capable of binding to DNA in a se-
quence-speci¢c manner and of recognizing regulatory sequen-
ces in distinct target genes. Sequence-speci¢c DNA binding
and a well de¢ned spatial and temporal expression pattern
are both prerequisites for the function of Sox proteins as
important developmental regulators [1,2].
Sox10 has been identi¢ed as a crucial transcription factor
for the development of vertebrate neural crest cells in a variety
of species including rodents, zebra¢sh, Xenopus and humans
[3^11]. Neural crest cells represent a highly mobile, pluripo-
tent population of ectodermal cells in the early embryo that
give rise to many di¡erent cell types and thus contribute to
numerous tissues throughout the body. Peripheral nervous
system and melanocytes are prominent examples of neural
crest derivatives. Interestingly, inactivation or deletion of
Sox10 has been reported to a¡ect many processes in neural
crest cells, including multipotency, proliferation, apoptosis,
survival and commitment to de¢ned neural crest-derived lin-
eages [3,12^14]. Even further roles of Sox10 during later
phases of development, in particular during terminal di¡er-
entiation, are strongly suggested by target gene analyses in
Sox10-de¢cient mice [15,16].
Neural crest development is sensitive to Sox10 gene dosage.
In mice and humans, those neural crest cells which give rise to
melanocytes or the enteric nervous system are most sensitive.
As a consequence, heterozygous loss of Sox10 already results
in partial loss of melanocytes and a missing innervation of the
distal colon [4,7]. The resulting pigmentation de¢cits and
aganglionosis of the distal colon give rise to a combined
Waardenburg^Hirschsprung syndrome in most patients carry-
ing heterozygous Sox10 mutations [9]. Homozygous Sox10
mutation obliterates melanocytes and the enteric nervous sys-
tem completely [3,5,7,17]. The importance of Sox10 for mela-
nocyte development has also been con¢rmed in Xenopus
where ectopic overexpression of Sox10 generated increased
numbers of melanocytes [10,11].
Recent studies have started to address the regulatory mech-
anisms that underlie Sox10 function by identifying target
genes. In melanocytes, Sox10 has been shown to regulate ex-
pression of the gene for the transcription factor Mitf [3,18^
20]. In vitro studies indicate that Sox10 functions through
direct activation of the melanocyte-speci¢c promoter of the
Mitf gene leading to a selective production of the melano-
cyte-speci¢c Mitf-M isoform [18^22]. Mitf-M in turn is a
key player in melanocyte development, as it in£uences mela-
nocyte survival through the antiapoptotic Bcl-2 [23], and reg-
ulates expression of many melanocyte markers including
tyrosinase, tyrosinase-related protein 1 and dopachrome
tautomerase (tyrosinase-related protein 2, Dct/Trp2) (for re-
view, see [24]). With Mitf being the critical regulator of mel-
anocyte development [24], it is possible to explain the mela-
nocyte defect in Sox10-de¢cient mice solely through Mitf
activation. In support of such a model, forced expression of
Mitf can rescue development of at least some melanocytes in
Sox10-de¢cient zebra¢sh with restoration of marker gene ex-
pression in these cells [19].
However, this does not exclude that there are additional
target genes for Sox10 in cells of the melanocyte lineage.
The gene for Dct/Trp2 is a good candidate for such a gene.
The encoded protein is an essential component of the ¢nal
phases of eumelanin synthesis in melanocytes as it converts
dopachrome to 5,6-dihydroxyindole-2-carboxylic acid [25,26].
It appears to be important for melanocyte detoxi¢cation and
is already expressed long before the start of melanin synthesis
[27]. By comparison of Dct/Trp2 expression with that of other
melanocyte markers, a transient loss of Dct/Trp2 expression
has previously been detected in Sox10þ=3 mouse embryos
between embryonic days 10.5 and 12.5 [3,28]. Additionally,
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Sox10 was able to activate reporter gene expression from the
5P £anking regions of both mouse and human Dct/Trp2 genes
[3,28]. These studies stopped short of analyzing whether
Sox10 in£uenced Dct/Trp2 expression directly through inter-
action with the Dct/Trp2 promoter. Given its in£uence on
Mitf expression, Sox10 could have functioned through Mitf
which also activates the Dct/Trp2 promoter [29,30]. Here, we
have analyzed the e¡ect of Sox10 on the Dct/Trp2 promoter.
Our studies indicate that Sox10 regulates Dct/Trp2 expression
both directly and indirectly via upregulation of Mitf with both
e¡ects reinforcing each other in the synergistic activation of
Dct/Trp2 expression by Sox10 and Mitf.
2. Materials and methods
2.1. Plasmids
Eukaryotic expression plasmids for human Sox10 and various mu-
tants have been described before [31]. pCMV-Mitf was generated by
inserting a V5-epitope tagged version of the cDNA for mouse M-Mitf
(gift of C. Goding) between HindIII and SmaI sites of pCMV5.
3.7 Trp2 luc, the luciferase reporter plasmid containing positions
33240 to +443 of the mouse Dct/Trp2 gene [3], was used to generate
several deletion mutants (2.2 Trp2 luc, 1.1 Trp2 luc, 0.9 Trp2 luc, 0.8
Trp2 luc, 0.75 Trp2 luc, 0.7 Trp2 luc, 0.5 Trp2 luc, see Fig. 1A) by
polymerase chain reaction-directed or enzymatic successive shortening
from the distal end. The replacement of potential Sox binding sites
within the Dct/Trp2 promoter by GC-rich sequences (1.1 Trp2 luc
construct, see Fig. 2A) was through the use of the QuickChange
Mutagenesis Kit (Stratagene).
For bacterial expression of Mitf, cDNA sequences corresponding to
the complete open reading frame of Mitf and an amino-terminal V5
tag were inserted into pGEX-KG as a HindIII/SmaI fragment.
2.2. Cell culture and luciferase assays
N2A neuroblastoma, HMB2 melanoma and COS cells were main-
tained in Dulbecco’s modi¢ed Eagle’s medium containing 5^10% fetal
calf serum. N2A and HMB2 cells were transfected using Superfect
reagent according to the manufacturer’s instructions (Qiagen), where-
as the DEAE-dextran method was used for COS cells as previously
described [32]. For luciferase assays, N2A and HMB2 cells were trans-
fected in duplicate in 24-well plates with 500 ng of luciferase reporter
plasmid and 50 ng of e¡ector plasmid per well if not stated otherwise.
Cells were harvested 48 h post transfection, and extracts were assayed
for luciferase activity.
2.3. Proteins, cell extracts, Western blots and electrophoretic mobility
shift assays
Mouse Mitf was produced in bacteria as a glutathione S-transferase
(GST) fusion protein and puri¢ed according to standard procedures
[33]. Extracts from transfected COS cells or HMB2 cells were pre-
pared and checked for expression of the protein of interest in Western
blots as described [34] using a polyclonal rabbit antiserum directed
against Sox10 [6] or a monoclonal against MITF (NeoMarkers).
For electrophoretic mobility shift assays, 0.5 ng of 32P-labeled
probe (for sequences see Figs. 2A, 3B and 6A) were incubated with
protein extracts from transfected COS cells for 20 min on ice in 20 Wl
reaction mixture containing 10 mM HEPES (pH 8.0), 5% glycerol, 50
mM NaCl, 5 mM MgCl2, 2 mM dithiothreitol, 0.1 mM EDTA, 4 Wg
of bovine serum albumin, and 1 Wg of poly(dGdC) or poly(dIdC) as
unspeci¢c competitor. Where indicated, 0.5 Wl GST antibody (Santa
Cruz Biotechnologies) was added. Samples were loaded onto native
4% polyacrylamide gels and electrophoresed in 0.5UTBE (45 mM
Tris/45 mM boric acid/1 mM EDTA, pH 8.3) at 120 V for 1.5 h.
Gels were dried and exposed for autoradiography.
3. Results
3.1. The Dct/Trp2 promoter is activated by Sox10
We have previously shown that Sox10 activates a reporter
gene under the control of a 3.7-kb fragment from the 5P reg-
ulatory region of the mouse Dct/Trp2 gene [3]. The setup used
in the original studies (inducible Sox10 expression in a stably
transfected cell line) yielded only modest activation rates and
therefore did not allow reliable mapping studies. For detailed
analysis of the 5P £anking region of the Dct/Trp2 gene, we
switched to transient co-transfection of N2A cells with Sox10
expression plasmid and luciferase reporter plasmid. We chose
N2A cells as these mouse neuroblastoma cells are neural crest-
derived, and should therefore possess an overall transcription-
al repertoire not too distant from melanocytes. Unlike mela-
nocytes, however, N2A cells do not express Sox10 [6] nor
Mitf-M (data not shown) so that results from transient trans-
fections are not complicated by endogenous background ex-
pression of these transcription factors. We optimized trans-
Fig. 1. The proximal Dct/Trp2 promoter is activated by Sox10 in
N2A cells. A: Schematic representation of luciferase reporter plas-
mids carrying successively shortened 5P £anking regions of the
mouse Dct/Trp2 gene. Numbers indicate positions of the last base
pairs still contained within the fragment on either side. The tran-
scriptional start is marked by an arrow. Negative values were as-
signed to positions preceding the transcription start site, positive
values to transcribed sequences. B: Transient transfections were per-
formed in N2A cells with the luciferase reporters depicted in A in
the absence or presence of Sox10. Data are presented as fold induc-
tionPS.E.M. with the activity for each reporter in the absence of
co-transfected Sox10 arbitrarily set to 1. C: Transient transfections
with the 1.1 Trp2 luc plasmid and increasing amounts of Sox10 ex-
pression plasmid (0.1 ng^1 Wg per well). Data are presented as rela-
tive activation rates, with the activation obtained with the highest
Sox10 concentration arbitrarily set to 100%. Luciferase activities in
B and C were determined in three independent experiments each
performed in duplicate.
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fection conditions such that we obtained on average a 29-fold
Sox10-dependent induction of reporter gene expression for the
same 3.7 kb Dct/Trp2 promoter fragment, for which we pre-
viously detected a three- to ¢ve-fold induction rate (Fig. 1B).
To map the Sox10-responsive elements within the 3.7-kb
fragment which includes 3240 bp preceding the transcriptional
start site of the Dct/Trp2 gene and 443 bp following it, we
generated a series of deletion mutants by successively short-
ening the 5P £anking region from the distal end (Fig. 1A). The
1.1 Trp2 luc construct (encompassing positions 3685 to +443)
retained full inducibility, indicating that the proximal pro-
moter of the Dct/Trp2 gene contains the cis-acting elements
which mediate Sox10 activity (Fig. 1B). While there was still
no change for the 0.9 Trp2 luc construct (encompassing posi-
tions 3465 to +443), activation rates dropped in a stepwise
fashion with further shortening, from a 30-fold to a 20-fold
induction after removal of sequences between 3465 and
3357, followed by a further reduction to seven-fold activation
rates after deletion of sequences between 3316 and 3245.
Sox10-dependent activation was completely lost in the 0.5
Trp2 luc construct (Fig. 1B) which corresponds to the mini-
mal promoter of the Dct/Trp2 gene (positions 360 to +443).
Thus we conclude that the proximal part of the Dct/Trp2
promoter between positions 3465 and 360 contains several
response elements which contribute to Sox10-dependent pro-
moter activation.
Titration experiments revealed that the amounts of expres-
sion plasmid used for our study was in the range where Sox10
yielded maximal activation. A further increase of Sox10 levels
left activation rates unchanged (Fig. 1C). Mutant Sox10 pro-
teins previously identi¢ed in human patients [9,31] failed to
activate the Dct/Trp2 promoter (Fig. 9, see below).
3.2. The Dct/Trp2 promoter contains multiple functionally
important binding sites for Sox10
The proximal Dct/Trp2 promoter (positions 3685 to 360)
was analyzed for potential Sox10 binding sites. Based on the
7-bp consensus for Sox binding sites (A/T)(A/T)CAA(A/T)G
[2], we identi¢ed six putative sites if we allowed for no more
than one mismatch that furthermore did not alter the con-
served CAA core (Fig. 2A). Using oligonucleotides carrying
each of these sites embedded in their natural environment,
electrophoretic mobility shift analyses were carried out (Fig.
2B). These studies con¢rmed that Sox10 is able to bind to all
of these sequences in principle, albeit with highly varying af-
¢nities. With constant amounts of Sox10 proteins and com-
parable speci¢c activities of all radiolabelled oligonucleotides,
sites 1 and 4 were bound most strongly, followed by sites 2
and 3. Sites 5 and 6 exhibited only weak binding. Complexes
between Sox10 and the various sites exhibited one of two
Fig. 2. Multiple Sox10 binding sites are present within the Dct/Trp2
promoter. A: Localization and sequence of Sox10 binding sites be-
tween positions 3685 and +443 of the proximal Dct/Trp2 promoter.
B: Electrophoretic mobility shift assay with extracts from mock-
transfected COS cells (3) or COS cells expressing the MIC variant
[31] of Sox10 (+). Oligonucleotides with sequences S1^S6 depicted
in A and C/CP which contained a dimeric Sox10 binding site from
the Protein zero promoter [15] were used as probes as indicated
above the lanes. m, bound monomer; d, bound dimer.
Fig. 3. Dimeric Sox10 binding to the Dct/Trp2 promoter. A: Elec-
trophoretic mobility shift assay with increasing amounts of extracts
from COS cells expressing Sox10 MIC using sites 4 (S4) and 5 (S5)
from the proximal Dct/Trp2 promoter as probes as indicated below
the lanes. C/CP from the Protein zero promoter served as positive
control for a dimeric site. (3) extract from mock-transfected COS
cells; (+) extract from Sox10 MIC expressing COS cells. m, bound
monomer; d, bound dimer. B: Sequence of oligonucleotides S4 and
mutant versions S4mut/4P and S4/4Pmut. C: Electrophoretic mobility
shift assay with the oligonucleotide probes shown in B using ex-
tracts from mock-transfected COS cells (3) or COS cells expressing
Sox10 MIC (+) as protein source. m, bound monomer; d, bound
dimer.
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mobilities (compare site 1 and site 4 in Fig. 2B). By compar-
ison to oligonucleotides of identical length which contained
Sox10 sites with well known binding modes (e.g. C/CP from
the Protein zero promoter in Fig. 2B), these two mobilities
were identi¢ed as corresponding to the monomeric and the
dimeric binding mode originally described for Sox10 and con-
¢rmed for the related Sox9 [35^37]. Thus monomeric binding
was strongest to site 1, whereas dimeric binding appeared to
be preferred on site 4. Dimeric binding was already prevalent
on site 4 at low Sox10 concentrations as expected when bind-
ing of the two participating Sox10 molecules is cooperative
(Fig. 3A). To further con¢rm that site 4 is a site that supports
binding of two Sox10 molecules to adjacent sites, we gener-
ated mutant oligonucleotides in which the originally predicted
Sox10 binding site or adjacent regions were replaced by GC-
rich sequences (Fig. 3B) previously found to be incompatible
with Sox10 binding [15]. The predicted Sox10 binding site
di¡ers in one position from the consensus motif. Replacement
of this site led to a strong reduction in Sox10 binding and a
concomitant shift from preferentially dimeric to monomeric
binding as evidenced by the increased mobility of the
Sox10^DNA complex (Fig. 3C). Mutation of the adjacent
upstream region caused a similar reduction in binding a⁄nity
and a switch to monomeric binding (Fig. 3C). Closer inspec-
tion revealed that this region contains a motif that deviates in
two positions from a consensus Sox binding site. Therefore,
the composite site 4 consists of two adjacent non-consensus
Sox10 binding sites in a head-to-tail orientation separated by
3 bp with one and two mismatches, respectively. The general
con¢guration is typical for many dimeric sites [16,35,38] ; the
exact spacing and orientation has not been found so far in
Sox10 response elements, but is highly similar to Sox9 binding
sites D and E in the enhancer of the collagen 11a2 gene [37].
Site 5 and site 6 also seem to bind two molecules of Sox10.
Because of the low a⁄nity and the low amounts of bound
Sox10, it was di⁄cult to distinguish whether binding of the
two Sox10 molecules was cooperative (Fig. 2B). We therefore
repeated electrophoretic mobility shift experiments with site 5
using Sox10 over a wide concentration range (Fig. 3A). With
increasing amounts of Sox10 protein, mobility of the protein^
DNA complex switches from a high-mobility complex to a
low-mobility complex. As the low-mobility complex becomes
predominant already under conditions where probe saturation
has not been achieved, we infer that binding of the ¢rst mol-
ecule of Sox10 to site 5 increases the likelihood of a second
molecule to bind to the same probe indicating that there is
some degree of Sox10 cooperativity on this site.
To analyze whether these binding sites contribute to Sox10-
dependent activation of the Dct/Trp2 promoter, we mutated
each site in the context of the 1.1 Trp2 luc reporter plasmid
(Fig. 4A) and assayed the consequences of each mutation on
Sox10-dependent reporter gene induction by transient trans-
fections (Fig. 4B). Compatible with a stepwise reduction of
Sox10 responsiveness in consecutively shortened Dct/Trp2
promoters, mutations of several sites led to lowered activa-
tion. The strongest e¡ect was observed following mutation of
site 1 which reduced Sox10-dependent induction by 60%. Mu-
tation of site 4 and site 5 decreased Sox10-dependent activa-
tion rates by 37% and 32%, respectively (Fig. 4B). For all
other sites, we were unable to reproducibly detect altered ac-
tivation rates in our assay system. We like to point out that
deletion and mutagenesis studies came to slightly di¡erent
conclusions (compare Figs. 1 and 4), as the contribution of
site 5 to Sox10-dependent activation of Dct/Trp2 became evi-
dent only in the mutagenesis study, whereas the importance of
site 6 can only be inferred from the deletion study. The under-
lying reason is currently unknown, but may result from the
respective presence or absence of modulatory transcription
factor sites in the reporter constructs. These minor inconsis-
tencies notwithstanding, both the high-a⁄nity monomeric site
1 and the high-a⁄nity dimeric site 4 were always among the
sites with e¡ects on Sox10-dependent activation of the Dct/
Trp2 promoter, indicating a reasonable correlation between
Sox10 binding a⁄nity and Sox10-mediated e¡ect.
To con¢rm that sites 1, 4 and 5 are indeed the Sox10 bind-
ing sites with the biggest contribution, we generated a triple
mutant in which all three sites were rendered inactive in the
context of the 1.1 Trp2 luc reporter. As expected, Sox10 re-
sponsiveness of the triple mutant is further reduced to residual
23% of wildtype levels (Fig. 4B).
We also investigated potential Sox10 e¡ects on the Dct/
Trp2 promoter in a human melanoma. In HMB2 cells,
Sox10 stimulated expression of the 0.75 Trp2 luc reporter
(encompassing positions 3316 to +443 of the Dct/Trp2
gene) 3.5-fold and left activity of the Dct/Trp2 minimal pro-
moter unaltered (Fig. 5B). Although present, Sox10-depen-
dent stimulatory e¡ects were thus less pronounced than in
N2A cells, probably due to the strong endogenous Sox10 ex-
pression in HMB2 cells (Fig. 5A). To study the in£uence of
endogenous Sox10, we compared the activity of the wildtype
1.1 Trp2 luc reporter with that of the triple mutant in sites 1,
4, and 5. As shown in Fig. 5C, expression was reduced by 88%
in the absence of the major Sox10 binding sites in the Dct/
Fig. 4. Sox10-dependent activation of the Dct/Trp2 promoter is
mediated by several Sox10 binding sites. A: Localization of Sox10
binding sites 1^6 (S1^S6) between positions 3685 and 360 of the
proximal Dct/Trp2 promoter. B: Transient transfections were per-
formed in N2A cells in the absence or presence of Sox10 with the
wildtype 1.1 Trp2 luciferase reporter (wt) or mutants in which
Sox10 binding to sites 1^6 (S1^S6) was abrogated. (mS1^mS6), sin-
gle site mutants. (mS1/4/5), triple mutant of sites 1, 4 and 5. Lucif-
erase activities in extracts from transfected cells were determined in
three independent experiments each performed in duplicate. The
data for mS1/4/5 were from separate transfection series which
yielded induction rates for the wildtype and mS1 constructs compa-
rable to the ones shown. Data are presented as relative activation
rates, with the Sox10-dependent activation obtained for the wildtype
construct arbitrarily set to 100%.
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Trp2 promoter. Thus, both ectopic and endogenous Sox10
activate the Dct/Trp2 promoter in melanoma cells.
3.3. The Dct/Trp2 promoter is synergistically activated by
Sox10 and Mitf
Sox10 binding site 1 is in the immediate vicinity of an
M-box that has previously been shown to confer most of
the Mitf responsiveness to the Dct/Trp2 promoter [29]. This
M-box bound Mitf with an a⁄nity comparable to the M-box
from the mouse tyrosinase promoter (Fig. 6A,B). The pres-
ence of Mitf in the obtained complex was veri¢ed by addition
of a speci¢c antibody and the resulting supershift (Fig. 6B).
Furthermore, Mitf-dependent activation of the Dct/Trp2 pro-
moter was roughly comparable in N2A cells to Sox10-depen-
dent activation and followed similar kinetics with maximal
induction rates being stable over a wide range of concentra-
tions (Fig. 6C).
When the 3.7 Trp2 luc reporter construct was co-trans-
fected with expression plasmids for both Sox10 and Mitf, a
clear synergistic activation of the Dct/Trp2 promoter was ob-
served (Fig. 7B). Whereas Sox10 or Mitf increased expression
44-fold and 57-fold, respectively, their combination led to a
dramatic 311-fold stimulation. We never observed comparable
stimulation rates for either protein alone. Activation rates in
the presence of both proteins were more than three-fold high-
er than the sum of single activation rates (Fig. 7C). Synergistic
activation was similarly achieved with the 1.1 Trp2 luc con-
struct. Upon further shortening of the Dct/Trp2 promoter to
positions 3316 to +443 (0.75 Trp2 luc in Fig. 7A), absolute
induction rates dropped signi¢cantly in the presence of both
Sox10 and Mitf, due to the lowered responsiveness of this
construct to each transcription factor (Fig. 7B). Reduction
of Mitf-dependent stimulation was probably caused by re-
moval of an E-box that has been shown to bind Mitf with
low a⁄nity [29]. However, induction was still synergistic (Fig.
7C). In contrast, no synergistic activation was observed for
the minimal Dct/Trp2 promoter. These results indicate that
Fig. 5. The proximal Dct/Trp2 promoter is activated by Sox10 in
melanoma cells. A: Western blot analysis of HMB2 cell extract
(HMB2) using a previously described polyclonal rabbit anti-Sox10
antiserum [6]. Extract from transiently transfected COS cells ex-
pressing ectopic Sox10 (Sox10) served as control. Molecular weight
markers in kDa are indicated on the left. B: Transient transfections
were performed in HMB2 cells with the 0.75 Trp2 luc and 0.5 Trp2
luc reporters in the absence (3Sox10) or presence (+Sox10) of ec-
topic Sox10. Data are presented as fold inductionPS.E.M. with the
activity for each reporter in the absence of co-transfected Sox10 ar-
bitrarily set to 1. C: Transient transfections of HMB2 cells with the
1.1 Trp2 luc plasmid in wildtype or triple mutant (mS1/4/5) version.
Data are presented as relative activation rates, with the activation
obtained for the wildtype construct arbitrarily set to 100%. Lucifer-
ase activities in B and C were determined in two independent ex-
periments each performed in duplicate.
Fig. 6. Mitf binds to and activates the Dct/Trp2 promoter. A: Se-
quence of oligonucleotide probes containing the M-boxes from the
mouse tyrosinase (Tyr M) and Dct/Trp2 promoters in wildtype
(Dct/Trp2 M) and mutant (Dct/Trp2 mM) version. B: Electropho-
retic mobility shift assay with (+) or without (3) GST-Mitf and oli-
gonucleotide probes from A. Antibodies directed against the GST
moiety (Ab) were added to the reaction resulting in a supershift of
the protein^DNA complex. C: Transient transfections with the 1.1
Trp2 luc plasmid and increasing amounts of Mitf expression plas-
mid (0.1 ng^1 Wg per well). Luciferase activities in extracts from
transfected cells were determined in three independent experiments
each performed in duplicate. Data are presented as fold induc-
tionPS.E.M. with the activity for each reporter in the absence of
co-transfected Mitf arbitrarily set to 1.
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cis-acting elements minimally required for synergistic activa-
tion of the Dct/Trp2 promoter are located in its proximal part
between positions 3316 and 360. Sequences between 3685
and 3316 furthermore seem to modulate this e¡ect.
To analyze whether the observed synergy requires direct
binding of Sox10 to the Dct/Trp2 promoter, we tested Dct/
Trp2 promoter constructs with mutations in various Sox10
binding sites for their ability to be synergistically activated
by Sox10 and Mitf. All mutant constructs exhibited compa-
rable Mitf-dependent activation rates (Fig. 8A,C). Mutation
of Sox10 binding site 1 reduced Sox10-dependent and overall
induction rates, but the residual activation remained synergis-
tic (Fig. 8A,B). Dct/Trp2 promoter constructs carrying muta-
tions in either Sox10 binding site 4 or site 5 exhibited induc-
tion rates virtually identical to those obtained for the wildtype
promoter (Fig. 8A). Synergy remained unaltered (Fig. 8B).
Thus, none of the Sox10 binding sites alone mediated synergy
which was lost only when a Dct/Trp2 promoter was used with
combined mutations in all three major Sox10 binding sites
(Fig. 8C,D). This argues that these three sites are involved
in the synergistic activation of the Dct/Trp2 promoter, but
can compensate for each other in this function.
A further set of Dct/Trp2 promoter mutants was generated
to address the role of M-box and Mitf binding to the Dct/
Trp2 promoter in synergy (Fig. 8E). Mutation of the M-box
in the context of the 1.1 Trp2 luc construct led to a drastic
reduction of Mitf responsiveness. Instead of a 49-fold induc-
tion, we now only observed an 11-fold induction of the Dct/
Trp2 promoter by Mitf. It is unlikely that the remaining Mitf-
dependent induction stems from residual binding to the
M-box, as the introduced mutation abolished Mitf binding
completely (Fig. 6B). The already mentioned E-box further
upstream in the Dct/Trp2 promoter [29] is probably respon-
sible. Sox10-dependent activation remained unaltered.
Despite the strong reduction of Mitf-dependent reporter
gene activation, we still observed a signi¢cant synergistic stim-
ulation of the Dct/Trp2 promoter by Sox10 and Mitf (Fig.
8F). This indicates that synergy can be achieved without Mitf
binding to the M-box. Synergy was lost, however, when mu-
tation of Sox10 binding site 1 was combined with mutation of
the immediately adjacent M-box.
To further analyze the molecular mechanism underlying the
observed synergy, Dct/Trp2 promoter activation studies were
carried out with mutant Sox10 proteins (Fig. 9A). If synergy
between Sox10 and Mitf is mediated mainly at the level of
DNA binding, Sox10 mutants still capable of DNA binding
should show at least some degree of synergy. This, however,
was not the case as evidenced for three di¡erent Sox10 pro-
teins with carboxy-terminal truncations, but intact HMG do-
main (Q377X, Y207X and MIC in Fig. 9B). Instead, removal
of 90 amino acids from the carboxy-terminal transactivation
domain already su⁄ced to abolish synergy completely (Fig.
9B). Activation rates were reduced even below the level ob-
tained with Mitf alone. We also failed to obtain synergistic
activation in the presence of a Sox10 variant, that is incapable
of DNA binding due to an insertion of two amino acids in the
DNA binding HMG domain, but is otherwise identical to the
wildtype (095 in Fig. 9B). Thus we conclude that although not
su⁄cient by themselves, both DNA binding and the presence
of a transactivation domain are important prerequisites for
synergy.
4. Discussion
4.1. Dct/Trp2 as a Sox10 target gene in melanocytes
Since its identi¢cation, Sox10 has been found to be an im-
portant transcriptional regulator in several cell types. Apart
from oligodendrocytes within the central nervous system
[16,39], all other Sox10-dependent cell types are derived
from neural crest cells and include glial cells of the peripheral
nervous system, chroma⁄n cells of the adrenal medulla, en-
teric neural crest and the pigment producing melanocytes [3^
5,7].
We have previously studied the function of Sox10 in periph-
eral glia, where Sox10 regulates at least two types of genes,
namely those responsible for early speci¢cation events [3] and
those conveying glial identity during terminal di¡erentiation
[15,38]. Target genes with functions in di¡erent processes and
stages of glial development are compatible with proposed
multiple roles of Sox10 in survival, proliferation, speci¢cation
and terminal di¡erentiation of glial cells [3,12,13].
The present study throws light on the nature of Sox10 tar-
get genes in melanocytes. It has previously been shown that
Sox10 directly regulates expression of the basic helix-loop-he-
lix leucine zipper protein Mitf which is involved both in mel-
anocyte speci¢cation and terminal di¡erentiation in a wide
variety of di¡erent species, and thus constitutes a critical reg-
ulator of melanocytes [18^22]. The epistatic relationship be-
tween Sox10 and Mitf could in principle account for most of
Fig. 7. Sox10 and Mitf synergistically activate the Dct/Trp2 pro-
moter. A: Schematic representation of Dct/Trp2 promoter deletion
constructs used to study synergy between Sox10 and Mitf. M-box
(black bar) and Sox10 binding sites (gray ellipses) mapped in the
Dct/Trp2 promoter are shown. B: Transient transfections were per-
formed in N2A cells with the luciferase reporters depicted in A in
presence of Sox10 (black bars), Mitf (white bars) or both proteins
(gray bars). Luciferase activities in extracts from transfected cells
were determined in three independent experiments each performed
in duplicate. Data are presented as fold inductionPS.E.M. with the
activity for each reporter in the absence of co-transfected transcrip-
tion factor arbitrarily set to 1. C: Synergy indices were determined
for each luciferase reporter shown in B by dividing the activation
rate obtained with the combination of Sox10 and Mitf by the sum
of the two activation rates obtained with either transcription factor
alone. An index of 1 (broken line) equals additive activation.
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the Sox10-dependent e¡ects on the melanocyte lineage [19]. In
agreement with such an assumption, forced expression of Mitf
in Sox10-de¢cient zebra¢sh rescued at least some melanocytes
[19]. Impressive as they are, these results might not necessarily
be transferable on a one to one scale from ¢sh to mammals.
Secondly, unphysiologically high Mitf levels during ectopic
expression could easily override additional signal transduction
pathways which are under Sox10 control, Mitf independent
and needed for melanocyte development under normal con-
ditions.
Here, we show that Dct/Trp2 is at least one additional
direct target gene for Sox10 in the melanocyte lineage, thus
strengthening the view that Sox10 might have functions in
melanocytes di¡erent from Mitf regulation. Dct/Trp2, the tar-
get identi¢ed in this study belongs to the group of genes that
de¢ne the melanocyte phenotype and is thus comparable to
several previously identi¢ed Sox10 targets which de¢ne a glial
phenotype such as the genes for Protein zero, connexin-32,
myelin basic protein and proteolipid protein [15,16,38].
4.2. Direct versus indirect regulation of Dct/Trp2 expression by
Sox10
Expression of Dct/Trp2 has previously been shown to be
under the control of the Mitf transcription factor [29]. Thus
Sox10 can in£uence Dct/Trp2 expression in two separate
ways, (i) indirectly by stimulating Mitf expression, and (ii)
directly by binding to the Dct/Trp2 promoter. This double
mode of action appears to be particularly important during
early embryonic development, as studies on mouse embryos
have revealed a transient Sox10-dependence of Dct/Trp2 ex-
pression from embryonic day 10.5^12.5 [28]. Mitf levels might
be initially below the threshold needed to activate Dct/Trp2
Fig. 8. Binding site requirements for synergistic activation of the Dct/Trp2 promoter. A,C,E: Transient transfections were performed in N2A
cells with the 1.1 Trp2 luc reporter in wildtype (wt) or mutant versions in the presence of Sox10 (black bars), Mitf (white bars) or both pro-
teins (gray bars). Mutations abrogated Sox10 binding to site 1 (mS1, mS1/M), site 4 (mS4), site 5 (mS5), or all three of these sites (mS1/4/5) as
well as Mitf binding to the M-box (mM, mS1/M). Luciferase activities in extracts from transfected cells were determined in three independent
experiments each performed in duplicate. Data are presented as fold inductionPS.E.M. with the activity for each reporter in the absence of co-
transfected transcription factor arbitrarily set to 1. B,D,F: Synergy indices were determined for each luciferase reporter shown in A,C,E by di-
viding the activation rate obtained with the combination of Sox10 and Mitf by the sum of the two activation rates obtained with either tran-
scription factor alone. An index of 1 (broken line) equals additive activation.
Fig. 9. Requirements of Sox10 domains for synergistic activation of
the Dct/Trp2 promoter. A: Schematic representation of wildtype
Sox10 and various mutant versions of the protein previously identi-
¢ed in human patients [9,31]. B: Transient transfections were per-
formed in N2A cells with the 1.1 Trp2 luc reporter and expression
plasmids for Mitf and the Sox10 proteins depicted in A either alone
or in combination. Luciferase activities in extracts from transfected
cells were determined in three independent experiments each per-
formed in duplicate. Data are presented as fold inductionPS.E.M.
with the activity for each reporter in the absence of co-transfected
transcription factor arbitrarily set to 1.
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expression. Alternatively, additional signalling pathways that
will assist Mitf in the activation of the Dct/Trp2 promoter at
later times might not yet be active during this early period so
that Sox10 has to pitch in. Both elevated cAMP levels and
Wnt signalling present candidates for such signalling path-
ways as they have been shown to activate the Dct/Trp2 pro-
moter in tissue culture systems [29,30].
Direct and indirect pathways for Sox10-dependent activa-
tion of the Dct/Trp2 promoter converge in the synergistic
activation of the Dct/Trp2 promoter by Mitf and Sox10.
This synergy might allow Sox10 to potentiate Mitf function
on the Dct/Trp2 promoter from day 10.5 to day 12.5 of em-
bryonic development. It is poorly understood how Sox10
manages to regulate di¡erent sets of target genes in di¡erent
Sox10-expressing cell types. Synergy between Sox10 and other
transcription factors with cell type-restricted expression might
be one of the mechanisms by which Sox10 function is modu-
lated in a cell speci¢c manner.
4.3. Mode of action of Sox10 on the Dct/Trp2 promoter
Analysis of the Dct/Trp2 promoter also reveals important
aspects about the mode of action of Sox10. In agreement with
¢ndings on other target gene promoters, Sox10 exerts its func-
tion through multiple binding sites [15,16,18]. The contribu-
tion of each binding site to the overall activation rate di¡ers
signi¢cantly, with one or few sites usually accounting for most
of the Sox10-dependent e¡ects. Six binding sites were identi-
¢ed in the proximal promoter of the Dct/Trp2 gene. Of these
sites, binding sites 1 and 4 were most important, as their
in£uence was strongest and detected both in deletion and
mutagenesis studies. Next were sites 5 and 6, which scored
in only of these studies. The contribution of each binding
site to Sox10-dependent activation of the Dct/Trp2 promoter
roughly correlated with the a⁄nity of each site for Sox10.
Accordingly, site 1 and site 4 exhibited the highest a⁄nity
for Sox10. The presence of multiple Sox10 binding sites,
each of which mediates part of the Sox10 response and binds
the protein with di¡erent a⁄nity, should make a promoter
exquisitely sensitive to Sox10 dosage e¡ects. This is indeed
the case for Dct/Trp2.
Many target gene promoters contain binding sites for single
Sox10 molecules as well as closely spaced sites that allow
binding of two Sox10 molecules in a cooperative manner
[15,16]. This ability for dimeric binding is a general feature
of Sox10 and its relatives Sox9 and Sox8 [35], and is essential
for their function both in vitro and in vivo [36,37]. The Dct/
Trp2 promoter also contains a high-a⁄nity dimeric site (site
4) as well as a high-a⁄nity monomeric site (site 1) which both
contribute signi¢cantly to the overall activation of the Dct/
Trp2 promoter by Sox10. Site 4 conforms to the overall struc-
ture of these dimer sites with at least one of the ‘half-sites’
being a non-consensus site with weak a⁄nity for single Sox10
molecules.
Some of the high-a⁄nity monomeric sites in other target
gene promoters are localized in close proximity to binding
sites for other transcription factors that also regulate the tar-
get gene in question. Thus, the major Sox10 binding site with-
in the Mitf promoter is in close proximity to a Pax3 binding
site, and both of these sites contribute signi¢cantly to syner-
gistic activation of the Mitf promoter by Pax3 and Sox10
[18,20]. As shown here, the monomeric Sox10 binding site 1
in the Dct/Trp2 promoter is immediately adjacent to the
M-box, which mediates most of the Mitf-dependent activation
of the Dct/Trp2 promoter [29].
4.4. Mechanism of synergy between Sox10 and Mitf
Given the close proximity of Sox10 binding site 1 and
M-box, it might have been expected that it is this composite
element that mediates synergistic activation of the Dct/Trp2
promoter by Sox10 and Mitf. However, this was not the case.
Surprisingly, synergy persisted both in the absence of a func-
tional M-box and in the absence of a functional Sox10 bind-
ing site 1. Synergy was only lost upon mutation of both sites.
Several explanations exist for this observation. If Sox10 and
Mitf were to interact directly, binding of one of the partners
to the composite element might be su⁄cient to keep both
proteins tethered to the Dct/Trp2 promoter. Such a mecha-
nism seems plausible as both Mitf and Sox10 have each been
shown to interact directly with other transcription factors
[30,40,41]. However, we failed to detect any direct interaction
between both proteins in GST pulldown experiments and co-
immunoprecipitation assays under various experimental set-
ups (data not shown). Similarly, no cooperative binding of
Mitf and Sox10 to the composite element was observed in
electrophoretic mobility shift assays (data not shown). While
all of this may be due to technical di⁄culties, there is at least
no strong evidence at present for a direct protein^protein
interaction between both transcription factors.
How can synergy be explained in the absence of a direct
protein^protein interaction between Sox10 and Mitf? Binding
of Sox10 to its many sites might help arrange the Dct/Trp2
promoter into a three-dimensional enhanceosome con¢gura-
tion of which Mitf is as much a part as other transcription
factors previously shown to bind or activate the Dct/Trp2
promoter such as CREB or Lef-1 [29,30]. Synergy could
then result from the combined interaction of enhanceosome
components with the transcription machinery or chromatin
remodeling activities. While minor interferences with Sox10
binding to the Dct/Trp2 promoter could be tolerated, substan-
tial binding loss would be incompatible with enhanceosome
formation and result in a loss of synergy. This could explain
why mutation of sites 1, 4 or 5 alone did not interfere with
synergy, whereas combined mutation of all three sites abol-
ished synergy completely. In the presence of full Sox10 bind-
ing activity, mutation of the M-box might be tolerated, be-
cause Mitf could still be recruited into the enhanceosome
through interaction with enhanceosome components other
than Sox10 such as Lef-1 [30,40] and through binding to an
E-box within the Dct/Trp2 promoter to which Mitf displays
weak a⁄nity [29]. Upon partial loss of Sox10 binding, how-
ever, the enhanceosome would be too much destabilized al-
ready to tolerate additional mutation of the M-box. Mitf
would no longer be recruited and as a consequence synergy
between Sox10 and Mitf is lost.
Whatever the exact mechanism through which synergy is
mediated, analyses of Sox10 mutants con¢rmed that synergy
is critically dependent on direct binding of Sox10 to the Dct/
Trp2 promoter. However, these studies also prove that DNA
binding alone is not su⁄cient. Additionally, the carboxy-ter-
minal transactivation domain of Sox10 is needed for synergis-
tic activation. In the context of the proposed enhanceosome
model, these results could mean that the transactivation do-
main of Sox10 provides interfaces with transcription or chro-
matin remodeling machineries. It strengthens our view that
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the observed synergy is not so much a result of increased
transcription factor binding to the Dct/Trp2 promoter, but a
result of improved crosstalk with transcriptional components
at a step subsequent to transcription factor binding.
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